Hormone Resistant Prostate Cancer Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02312557Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideTreatment